(Q39818772)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21063787%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

title

Current management practices for acromegaly: an international survey (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21063787%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21063787%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Peter J. Trainer

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21063787%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

5

E Ghigo

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21063787%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1

A Giustina

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21063787%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

author name string

M D Bronstein

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21063787%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

F F Casanueva

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21063787%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

K K Y Ho

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21063787%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

A Klibanski

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21063787%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

S Lamberts

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21063787%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

S Melmed

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21063787%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

publication date

1 June 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21063787%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21063787%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

volume

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21063787%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21063787%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

page(s)

125-133

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21063787%20AND%20SRC:MED&resulttype=core&format=json

Acromegaly pathogenesis and treatment

16 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0269-9

Epidemiology of acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0269-9

High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0269-9

High prevalence of biochemical acromegaly in primary care patients with elevated IGF-1 levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0269-9

Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0269-9

Sleep apnoea syndrome is highly prevalent in acromegaly and only partially reversible after biochemical control of the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0269-9

Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0269-9

Consensus statement: medical management of acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0269-9

Guidelines for acromegaly management: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0269-9

Guidelines for the treatment of growth hormone excess and growth hormone deficiency in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0269-9

Diagnosis and treatment of acromegaly complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0269-9

A consensus on criteria for cure of acromegaly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0269-9

Guidelines for acromegaly management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0269-9

Assessment of the awareness and management of cardiovascular complications of acromegaly in Italy. The COM.E.T.A. (COMorbidities Evaluation and Treatment in Acromegaly) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0269-9

The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0269-9

Medical progress: Acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0269-9

Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0269-9

Basal and glucose-suppressed GH levels less than 1 microg/L in newly diagnosed acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0269-9

Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0269-9

High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0269-9

Outcome of transphenoidal surgery for acromegaly and its relationship to surgical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0269-9

Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0269-9

Influence of growth hormone receptor d3 and full-length isoforms on biochemical treatment outcomes in acromegaly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0269-9

A nationwide survey of mortality in acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0269-9

Relationship between disease-related morbidity and biochemical markers of activity in patients with acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0269-9

Pegvisomant in acromegaly: why, when, how.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0269-9

Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0269-9

Long-term effects of the combination of pegvisomant with somatostatin analogs (SSA) on glucose homeostasis in non-diabetic patients with active acromegaly partially resistant to SSA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0269-9

Wide variation in surgical outcomes for acromegaly in the UK

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-010-0269-9

Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs.

21 January 2018

1 reference

12 December 2020

Factors influencing mortality in acromegaly

1 reference

12 December 2020

Criteria for cure of acromegaly: a consensus statement

1 reference

12 December 2020

Changing patterns in diagnosis and therapy of acromegaly over two decades

1 reference

12 December 2020

1 reference

12 December 2020

10.1007/S11102-010-0269-9

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21063787%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1 reference